Christopher Wolfram

Christopher Wolfram

Auto-generated profile, based on publicly available information

Christopher Wolfram

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin (CBF) , Hindenburgdamm 30, Berlin 12203

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
TGTeresa Gerhardt
Teresa Gerhardt
CSClaudio Seppelt
Claudio Seppelt
YAYoussef Abdelwahed
Youssef Abdelwahed
DMDenitsa Meteva
Denitsa Meteva
CWChristopher Wolfram
Christopher Wolfram
FGfor the OPTICO-ACS study group
for the OPTICO-ACS study group
Rupture of the fibrous cap (RFC) and erosion of an intact fibrous cap (IFC) are the two predominant mechanisms causing acute coronary syndromes (ACS). It is uncertain whether clinical outcomes are different following RFC-ACS vs. IFC-ACS and whether this is affected by a specific inflammatory response. The prospective, translational OPTIcal-COherence Tomography in Acute Coronary Syndrome study programme investigates the impact of the culprit lesion phenotype on inflammatory profiles and prognosis in ACS patients. This analysis included 398 consecutive ACS patients, of which 62% had RFC-ACS and 25% had IFC-ACS. The primary endpoint was a composite of cardiac death, recurrent ACS, hospitalization for unstable angina, and target vessel revascularization at 2 years [major adverse cardiovascular events (MACE+)]. Inflammatory profiling was performed at baseline and after 90 days. Patients with IFC-ACS had lower rates of MACE+ than those with RFC-ACS (14.3% vs. 26.7%, P = 0.02). In 368-plex proteomic analyses, patients with IFC-ACS showed lower inflammatory proteome expression compared with those with RFC-ACS, including interleukin-6 and proteins associated with the response to interleukin-1β. Circulating plasma levels of interleukin-1β decreased from baseline to 3 months following IFC-ACS (P < 0.001) but remained stable following RFC-ACS (P = 0.25). Interleukin-6 levels decreased in patients with RFC-ACS free of MACE+ (P = 0.01) but persisted high in those with MACE+. This study demonstrates a distinct inflammatory response and a lower risk of MACE+ following IFC-ACS. These findings advance our understanding of inflammatory cascades associated with different mechanisms of plaque disruption and provide hypothesis generating data for personalized anti-inflammatory therapeutic allocation to ACS patients, a strategy that merits evaluation in future clinical trials. ACS, acute coronary syndrome; IFC, intact fibrous cap; IL-6, interleukin-6; LDLC, low-density lipoprotein cholesterol; MACE+, major adverse cardiovascular events, MΦ, macrophage; RFC, ruptured fibrous cap; TCFA, thin-cap fibro-atheroma. ns, not significant; *P < 0.05.

9 August 2025 in Cardiovascular Research
Verified
Journal Article
Closed access
PSPhilip Stapmanns
Philip Stapmanns
YAYoussef S Abdelwahed
Youssef S Abdelwahed
CWChristopher Wolfram
Christopher Wolfram
ESElisabeth Strässler
Elisabeth Strässler
AHArash Haghikia
Arash Haghikia
TGTeresa Gerhardt
Teresa Gerhardt